PROCTER & GAMBLE HEALTH | JAGSON PHAR | PROCTER & GAMBLE HEALTH/ JAGSON PHAR |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | 37.3 | 92.9% | View Chart |
P/BV | x | 10.6 | 6.1 | 173.4% | View Chart |
Dividend Yield | % | 2.0 | 1.4 | 139.0% |
PROCTER & GAMBLE HEALTH JAGSON PHAR |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
JAGSON PHAR Mar-23 |
PROCTER & GAMBLE HEALTH/ JAGSON PHAR |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 420 | 1,276.9% | |
Low | Rs | 3,883 | 254 | 1,528.7% | |
Sales per share (Unadj.) | Rs | 740.7 | 90.3 | 819.9% | |
Earnings per share (Unadj.) | Rs | 138.2 | 10.2 | 1,355.4% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 10.7 | 1,455.7% | |
Dividends per share (Unadj.) | Rs | 95.00 | 5.00 | 1,900.0% | |
Avg Dividend yield | % | 2.1 | 1.5 | 138.5% | |
Book value per share (Unadj.) | Rs | 447.6 | 57.3 | 781.2% | |
Shares outstanding (eoy) | m | 16.60 | 26.20 | 63.4% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 3.7 | 167.3% | |
Avg P/E ratio | x | 33.5 | 33.1 | 101.2% | |
P/CF ratio (eoy) | x | 29.8 | 31.6 | 94.2% | |
Price / Book Value ratio | x | 10.3 | 5.9 | 175.6% | |
Dividend payout | % | 68.7 | 49.0 | 140.2% | |
Avg Mkt Cap | Rs m | 76,761 | 8,831 | 869.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 652 | 316.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 2,367 | 519.5% | |
Other income | Rs m | 184 | 57 | 320.7% | |
Total revenues | Rs m | 12,480 | 2,424 | 514.8% | |
Gross profit | Rs m | 3,247 | 307 | 1,057.9% | |
Depreciation | Rs m | 281 | 12 | 2,332.0% | |
Interest | Rs m | 8 | 4 | 186.4% | |
Profit before tax | Rs m | 3,142 | 348 | 902.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 81 | 1,047.7% | |
Profit after tax | Rs m | 2,295 | 267 | 858.8% | |
Gross profit margin | % | 26.4 | 13.0 | 203.6% | |
Effective tax rate | % | 27.0 | 23.2 | 116.1% | |
Net profit margin | % | 18.7 | 11.3 | 165.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 1,722 | 680.3% | |
Current liabilities | Rs m | 6,791 | 352 | 1,930.1% | |
Net working cap to sales | % | 40.0 | 57.9 | 69.2% | |
Current ratio | x | 1.7 | 4.9 | 35.2% | |
Inventory Days | Days | 263 | 9 | 2,789.6% | |
Debtors Days | Days | 343 | 32 | 1,067.2% | |
Net fixed assets | Rs m | 10,617 | 304 | 3,493.9% | |
Share capital | Rs m | 166 | 131 | 126.7% | |
"Free" reserves | Rs m | 7,265 | 1,370 | 530.2% | |
Net worth | Rs m | 7,431 | 1,501 | 495.0% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 2,026 | 1,102.4% | |
Interest coverage | x | 409.1 | 85.3 | 479.7% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 1.2 | 47.1% | |
Return on assets | % | 10.3 | 13.4 | 77.0% | |
Return on equity | % | 30.9 | 17.8 | 173.5% | |
Return on capital | % | 42.4 | 23.5 | 180.7% | |
Exports to sales | % | 0 | 2.3 | 0.0% | |
Imports to sales | % | 13.1 | 0 | - | |
Exports (fob) | Rs m | NA | 55 | 0.0% | |
Imports (cif) | Rs m | 1,605 | NA | - | |
Fx inflow | Rs m | 1,465 | 55 | 2,650.5% | |
Fx outflow | Rs m | 1,605 | 41 | 3,919.4% | |
Net fx | Rs m | -140 | 14 | -979.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 467 | 505.8% | |
From Investments | Rs m | -215 | -577 | 37.3% | |
From Financial Activity | Rs m | -985 | -5 | 21,547.0% | |
Net Cashflow | Rs m | 1,160 | -115 | -1,011.3% |
Indian Promoters | % | 0.0 | 24.8 | - | |
Foreign collaborators | % | 51.8 | 43.3 | 119.6% | |
Indian inst/Mut Fund | % | 20.0 | 1.6 | 1,263.9% | |
FIIs | % | 6.2 | 0.7 | 854.8% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 31.9 | 151.0% | |
Shareholders | 56,778 | 16,282 | 348.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | JAGSON PHAR | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 3.04% | 0.45% |
1-Month | -1.15% | 25.24% | 2.55% |
1-Year | 0.73% | -0.63% | 56.14% |
3-Year CAGR | -8.76% | 51.77% | 15.22% |
5-Year CAGR | 4.97% | 68.35% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the JAGSON PHAR share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of JAGSON PHAR the stake stands at 68.1%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of JAGSON PHAR.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
JAGSON PHAR paid Rs 5.0, and its dividend payout ratio stood at 49.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of JAGSON PHAR.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.